Open AccessLncRNA BANCR Attenuates the Killing Capacity of Cisplatin on Gastric Cancer Cell Through the ERK1/2 Pathway
Author(s) -
Miao Xiang,
Yixiang Liu,
Yuzhu Fan,
Guoqiang Wang,
Haoshuai Zhu
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s269679
Subject(s) - cisplatin , cancer , cancer research , cancer cell , cell growth , long non coding rna , clonogenic assay , mapk/erk pathway , cell , medicine , signal transduction , biology , downregulation and upregulation , chemotherapy , gene , microbiology and biotechnology , biochemistry
Chemotherapy-based comprehensive treatments are the most important therapeutic methods for patients with advanced gastric cancer, but chemoresistance often cause treatment failure. Long non-coding RNA (LncRNA) BRAF-activated non-coding RNA (BANCR) has been shown to participate in many biological behaviors of multiple cancers. However, the biological roles of LncRNA BANCR in chemoresistance of gastric cancer remain unclear. Here, we aimed to evaluate the functions of LncRNA BANCR on the therapy of gastric cancer.